Table 1.

Joint effect survival analysis of the risk score model and clinical parameters in sarcoma

Group	Risk score	Variables	Patients (n = 257)	MST (d)	Crude HR (95% CI)	Crude P	Adjusted HR (95% CI)	Adjusted P c
		Age (y)
A	Low risk	≤65	84	2694	1		1
B	Low risk	>65	45	1953	2.025 (1.071‐3.830)	.030	1.848 (0.959‐3.558)	.066
C	High risk	≤65	73	1970	1.905 (1.062‐3.417)	.031	2.128 (1.172‐3.861)	.013
D	High risk	>65	55	1049	4.918 (2.784‐8.689)	<.001	4.895 (2.741‐8.742)	<.001
		Residual tumor a
a	Low risk	R0	77	NA	1		1
b	Low risk	R1/R2/Rx	51	1953	2.939 (1.532‐5.640)	.001	2.297 (1.159‐4.553)	.014
c	High risk	R0	76	1649	2.519 (1.347‐4.712)	.004	2.383 (1.266‐4.485)	.007
d	High risk	R1/R2/Rx	52	1049	6.435 (3.427‐12.084)	<.001	5.454 (2.853‐10.425)	<.001
		Tumor multifocal b
I	Low risk	Single	97	NA	1		1
II	Low risk	Multiple	23	2034	2.233 (1.130‐4.414)	.021	1.705 (0.834‐3.484)	.143
III	High risk	Single	91	1466	2.454 (1.468‐4.100)	.001	2.353 (1.404‐3.944)	.001
IV	High risk	Multiple	26	1366	3.446 (1.734‐6.848)	<.001	3.289 (1.644‐6.579)	.001

Abbreviations: CI, confidence interval; HR, hazard rate; MST, median survival time; NA, not available.

^aInformation of residual tumor was unavailable in one patients.

^bInformation of tumor multifocal was unavailable in 20 patients.

^cAdjusted for age, residual tumor, and tumor multifocal.